Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Your ultimate guide to the 2024 North Carolina State Fair
Recommended
Help North Carolina rebuild: WRAL's Hurricane Helene recovery fund raises $900K+
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amphera B.V.
MesoPher Cell Therapy Increases 2-Year RFS Rate in Resected Pancreatic Cancer by 50%; Amphera Announces Publication of Phase II Results in Journal of Clinical Oncology and Orphan Designation Granted by FDA & EMA
September 25, 2024
From
Amphera B.V.
Via
Business Wire
Amphera Announces a Positive Opinion of the European Medicines Agency on the Granting of Orphan Medicinal Product Designation for MesoPher in Pancreatic Cancer
June 06, 2023
From
Amphera B.V.
Via
Business Wire
Amphera Announces Clinical Updates of MesoPher Cell Therapy
December 12, 2022
From
Amphera B.V.
Via
Business Wire
Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma
August 01, 2022
From
Amphera B.V.
Via
Business Wire
Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma
December 08, 2021
From
Amphera B.V.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.